SYGNIS AG

euro adhoc: LION bioscience AG
Strategic management decisions
LION bioscience sells bioinformatics business, Dr. Thure Etzold resigns as CEO

-------------------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. -------------------------------------------------------------------------------- 04.04.2006 Ad-hoc Release LION bioscience sells bioinformatics business Dr. Thure Etzold resigns as CEO Heidelberg, April 4, 2006 - LION bioscience AG today announced the successful completion of the sales process regarding its bioinformatics business. As of April 4, 2006 the bioinformatics business, consisting of the subsidiaries LION Bioscience Ltd, Cambridge UK and LBAV Inc., Cambridge, MA, USA is transferred to BioWisdom Ltd., Cambridge, UK. The sales price is up to 4 Mio E. In this context, Dr. Thure Etzold, original inventor of the SRS technology and current CEO of LION, will resign from the LION board as of April 4, 2006 as planned. For further information, please contact: |Peter Willinger | |Chief Financial Officer | |Tel: +49 (0) 6221-4038 293 | |Email: | |peter.willinger@lionbioscience.com | ### Except for the historical information contained herein, the matters set forth in this press release are forward looking. These forward-looking statements may include projections, assumptions, estimates, targets, and descriptions of future events. Such statements are based on currently available information and on LION's current expectations as to future events that may not prove to be accurate. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Many factors could cause the actual results, performance or achievements of LION to be materially different from those that may be projected, expected, targeted, expressed or implied by such statements. All roll-out plans and future dates with respect to completion of development and market release of LION products are target dates only based on the company's current planning and may change in the future. Any delays in the current product release schedule will have a materially adverse effect on the company's targets for fiscal year. ### end of announcement euro adhoc 04.04.2006 15:11:53 -------------------------------------------------------------------------------- ots Originaltext: LION Bioscience AG Im Internet recherchierbar: http://www.presseportal.de Further inquiry note: Stephan Trautvetter Director Finance & Accounting Telefon: +49(0)6221 4038 476 E-Mail: stephan.trautvetter@lionbioscience.com Branche: Biotechnology ISIN: DE0005043509 WKN: 504350 Index: CDAX, Prime All Share, Technologie All Share Börsen: Frankfurter Wertpapierbörse / regulated dealing/prime standard New York / ADR Börse Berlin-Bremen / free trade Hamburger Wertpapierbörse / free trade Baden-Württembergische Wertpapierbörse / free trade Börse Düsseldorf / free trade Niedersächsische Börse zu Hannover / free trade Bayerische Börse / free trade

Das könnte Sie auch interessieren: